Clinical trials: Insufficient Metabolic Control
Diabetes Mellitus, Type 2
Efficacy and Safety of Empagliflozin Versus Sitagliptin in Patients With Type 2 Diabetes
The purpose of this study is to assess safety and efficacy of empagliflozin compared to sitagliptin in patients with type 2 diabetes mellitus who are treatment-naive or on treatment with metformin and have insufficient glycaemic…
- Trial name
- NCT01984606
- Testing
- Empagliflozin, Sitagliptin
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus, Type 2 Diabetes
Study to Assess Safety & Efficacy of Sitagliptin as Initial Oral Therapy for Treatment of Type 2 Diabetes Mellitus in Pediatric Participants. (MK-0431-083)
The purpose of the study is to assess the safety of the addition of sitagliptin, and its effect on hemoglobin A1c (A1C) in pediatric participants 10-17 years of age with type 2 diabetes mellitus (T2DM) with inadequate glycemic…
- Trial name
- NCT01485614
- Testing
- Sitagliptin, Metformin, Glycemic Rescue 1
- Volunteers
- 200 people
- Sponsor
- Merck Sharp & Dohme LLC
Type 2 Diabetes Mellitus
A Phase 3 Study to Evaluate the Efficacy and Safety of ORMD-0801 in Subjects With Type 2 Diabetes Mellitus.
ORA-013-3 is a randomized, controlled study to test the efficacy and safety of an oral capsule of ORMD-0801 at several doses in patients with Type 2 Diabetes Mellitus (T2DM) who have not responded well to other glucose-lowering…
- Trial name
- NCT06731075
- Testing
- ORMD-0801 8 mg, ORMD-0801 16 mg
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- Oramed, Ltd.
Type 2 Diabetes Mellitus
Confirmatory Study of MT-2412 in Japanese Patients With Type 2 Diabetes (Add-on Study of Teneligliptin)
The purpose of this study is to evaluate the efficacy and safety of co-administration of Canagliflozin (TA-7284) and Teneligliptin (MP-513) once daily for 24 weeks in Japanese patients with Type 2 diabetes mellitus who are…
- Trial name
- NCT02354222
- Testing
- Canagliflozin, Teneligliptin
- Where
- 3 sites in Japan
- Volunteers
- 154 people
- Sponsor
- Tanabe Pharma Corporation
Type 2 Diabetes Mellitus
Study of Sitagliptin for the Treatment of Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Insulin (MK-0431-260)
The purpose of this study is to examine the insulin-sparing effect of sitagliptin 100 mg once-daily compared with placebo over 24 weeks in participants with type 2 diabetes mellitus who have inadequate glycemic control on insulin…
- Trial name
- NCT01462266
- Testing
- Sitagliptin, Insulin Glargine, Metformin
- Volunteers
- 660 people
- Sponsor
- Merck Sharp & Dohme LLC
Type 2 Diabetes Mellitus
A Study to Assess the Efficacy and Safety of Ipragliflozin in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin
The main purpose of this study is to evaluate the efficacy in reducing glycated hemoglobin of ipragliflozin in combination with metformin compared with metformin plus placebo in subjects with type 2 diabetes mellitus who have…
- Trial name
- IMPRESSION (NCT02794792)
- Testing
- Ipragliflozin L-proline, Metformin
- Where
- 14 sites in Russia
- Volunteers
- 268 people
- Sponsor
- Astellas Pharma Europe B.V.
Diabetes Mellitus, Type 2
A Study Comparing Insulin Intensification Therapies in Patients With Type 2 Diabetes Mellitus
The purpose of the study is to compare the effects on overall glycaemic control of two insulin intensification therapies.
- Trial name
- NCT01175811
- Testing
- Insulin Lispro Premix, Insulin Glargine, Insulin Lispro
- Where
- 14 sites in China, South Korea and 1 more
- Volunteers
- 402 people
- Sponsor
- Eli Lilly and Company
Diabetes
Phase III Insulin Add-On Asia Regional Program - ST
The purpose is to determine if after 24 weeks of oral daily administration, there will be a greater mean reduction from baseline in glycosylated hemoglobin (HbA1c) achieved with Dapagliflozin 10 mg plus insulin compared to…
- Trial name
- NCT02096705
- Testing
- Dapagliflozin
- Where
- 29 sites in China, Singapore and 1 more
- Volunteers
- 477 people
- Sponsor
- AstraZeneca
Diabetes Mellitus, Type 2
Saxagliptin Treatment in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise
The purpose of this clinical research study is to learn whether saxagliptin (BMS-477118) is more effective than placebo as a treatment for type 2 diabetic subjects who are not sufficiently controlled with diet and exercise
- Trial name
- NCT00121641
- Testing
- Saxagliptin, Metformin
- Where
- 134 sites in United States, Australia and 4 more
- Volunteers
- 1,035 people
- Sponsor
- AstraZeneca
Type 2 Diabetes Mellitus
A Study to Assess the Efficacy and Safety of ASP1941 in Combination With Sulfonylurea in Type 2 Diabetic Patients
This study is to evaluate the efficacy and safety after concomitant administration of ASP1941 and sulfonylurea in patients with diabetes mellitus.
- Trial name
- NCT01242215
- Testing
- ipragliflozin, Sulfonylurea
- Where
- 7 sites in Japan
- Volunteers
- 243 people
- Sponsor
- Astellas Pharma Inc
Type 2 Diabetes
Study to Evaluate the Safety and Efficacy of the Addition of Omarigliptin (MK-3102) Compared With the Addition of Sitagliptin in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-026)
This is a non-inferiority study comparing omarigliptin with sitagliptin in participants with type 2 diabetes mellitus (T2DM) with inadequate glycemic control on metformin therapy.
- Trial name
- NCT01841697
- Testing
- Omarigliptin, Sitagliptin, Open-label Metformin
- Volunteers
- 642 people
- Sponsor
- Merck Sharp & Dohme LLC
Type 2 Diabetes
A Study of HRS-7535 Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequately Controlled With Metformin
The aim of this trial is to evaluate the efficacy and safety of HRS-7535 compared with dapagliflozin in subjects with type 2 diabetes mellitus with inadequate glycemic control using metformin.
- Trial name
- NCT06589765
- Testing
- HRS-7535 tablet, dapagliflozin tablet
- Where
- China
- Volunteers
- 810 people
- Sponsor
- Shandong Suncadia Medicine Co., Ltd.
Diabetes Mellitus, Type 2
A Study of Insulin Lispro Mix in Type 2 Diabetic Asian Patients
The purpose is to evaluate the proportion of subjects achieving a Hemoglobin A1c (HbA1c) level below 6.5%, when lispro mix 50/50 is introduced in a stepwise manner from every day (QD) administration to type 2 diabetic patients…
- Trial name
- SIMPLE (NCT00971997)
- Testing
- Lispro Mix 50/50
- Where
- 14 sites in Japan
- Volunteers
- 135 people
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes Mellitus
A Study of the Efficacy and Safety of MK-0431D (a Fixed-dose Combination of Sitagliptin and Simvastatin) for the Treatment of Participants With Type 2 Diabetes Mellitus (T2DM) With Inadequate Glycemic Control on Metformin Monotherapy (MK-0431D-266)
The purpose of this study is to assess the efficacy and safety of sitagliptin/simvastatin fixed-dose combination (FDC) in participants with T2DM who have inadequate glycemic control while on metformin monotherapy.
- Trial name
- NCT01678820
- Testing
- Sitagliptin/Simvastatin FDC, Sitagliptin, Simvastatin
- Volunteers
- 299 people
- Sponsor
- Merck Sharp & Dohme LLC
Type 2 Diabetes Mellitus
Ertugliflozin vs. Glimepiride in Type 2 Diabetes Mellitus (T2DM) Participants on Metformin (MK-8835-002)
This study will evaluate the efficacy and safety of the addition of ertugliflozin (MK-8835/PF-04971729) compared with the addition of glimepiride in participants with T2DM who have inadequate glycemic control on metformin.
- Trial name
- NCT01999218
- Testing
- Ertugliflozin 5 mg, Ertugliflozin 10 mg, Glimerpiride
- Volunteers
- 1,326 people
- Sponsor
- Merck Sharp & Dohme LLC
Type 2 Diabetes
A Study of Orforglipron (LY3502970) in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone
The main purpose of this study is to determine safety and efficacy of orforglipron compared with placebo in adult participants with type 2 diabetes and inadequate glycemic control with diet and exercise alone.
- Trial name
- ACHIEVE-1 (NCT05971940)
- Testing
- Orforglipron
- Where
- 89 sites in United States, China and 4 more
- Volunteers
- 559 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 2
BI 10773 add-on to Metformin in Patients With Type 2 Diabetes
The objective of the current study is to investigate the efficacy, safety and pharmacokinetics of five doses of BI 10773 compared to placebo given for 12 weeks as add-on therapy to on going metformin therapy in patients with T2DM…
- Trial name
- NCT00749190
- Testing
- BI 10773, sitagliptin
- Where
- 116 sites in United States, Argentina and 14 more
- Volunteers
- 495 people
- Sponsor
- Boehringer Ingelheim
Type 2 Diabetes Mellitus
A Study to Test the Safety and Efficacy of Adding Sitagliptin in Patients With Type 2 Diabetes Mellitus (MK0431-074)
A study to assess the safety and efficacy of the addition of sitagliptin compared to placebo in patients with Type 2 Diabetes Mellitus who have inadequate glycemic control on metformin.
- Trial name
- NCT00813995
- Testing
- Comparator: Sitagliptin phosphate
- Volunteers
- 395 people
- Sponsor
- Merck Sharp & Dohme LLC
Type 2 Diabetes Mellitus
A Study to Assess the Addition of Sitagliptin to Metformin Compared With the Addition of Dapagliflozin to Metformin in Participants With Type 2 Diabetes Mellitus (T2DM) and Mild Renal Impairment Who Have Inadequate Glycemic Control on Metformin With or Without a Sulfonylurea (MK-0431-838)
The purpose of the study is to assess the effect of the addition of sitagliptin to metformin with or without a sulfonylurea compared with the addition of dapagliflozin to metformin with or without a sulfonylurea on hemoglobin A1c…
- Trial name
- NCT02532855
- Testing
- Sitagliptin, Dapagliflozin, Metformin
- Volunteers
- 614 people
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes Mellitus, Non-Insulin-Dependent
Addition Of Januvia (Sitagliptin) Improves Glycemic Control In Patients Inadequately Controlled By Metformin (MK0431-078)
To compare the efficacy of three strategies of lifestyle changes associated with Januvia (sitagliptin) 100 mg/day in patients with Type 2 Diabetes Mellitus (T2DM) inadequately controlled by metformin (hemoglobin A1c [HbA1c]…
- Trial name
- NCT00545584
- Testing
- sitagliptin phosphate, Comparator: Diet, Comparator: Physical Activity
- Volunteers
- 1,512 people
- Sponsor
- Merck Sharp & Dohme LLC